Application of endocrine therapy combined with paclitaxel (albumin bound) in patients with intermediate and advanced prostate cancer
10.3781/j.issn.1000-7431.2017.44.095
- Author:
Zhiyong YANG
1
Author Information
1. Department of Medical Oncology, Xining Haihu Hospital
- Publication Type:Journal Article
- Keywords:
Drug therapy, combination;
Endocrine disruptors;
Prostatic neoplasms
- From:
Tumor
2017;37(7):782-787
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the efficacy of icalutamide and goserelincombined with paclitaxel (albumin bound) and prednisone in patientswith intermediate and advanced prostate cancer.Methods: One hundred patients with intermediate and advancedprostate cancer were randomly divided into control group (n = 50)and observation group (n = 50). The patients in the control groupwere treated with oral bicalutamide and goserelin acetate sustainedrelease.The patients in the observation group were treated with oral bicalutamide, goserelin acetate sustained-release, paclitaxel (albumin bound) andprednisone. After 3 cycles of treatment, the effects and adverse reactions were compared.Results: The complete remission rate and the partial remission rate of the observationgroup were higher than those in the control group (22.0% vs 8%, 60% vs 40%, both P <0.05). The median survival time and the median progression-free survival time of theobservation group were longer than those of the control group (51 months vs 33 months,54 months vs 30 months, both P < 0.05). The serum prostate specific antigen, prostatevolume and maximum urine flow rate of the patients in the observation group wereimproved. The adverse reactions between the two groups had no significant differences (allP > 0.05).Conclusion: The endocrine therapy combined with paclitaxel (albumin bound) and prednisonein patients with intermediate and advanced prostate cancer can achieve good efficacy.
